Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 9:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: off-loading Clear all
Terminated Not applicable Interventional Accepts healthy volunteers

Effectiveness of a Knee Brace When Combined With Viscosupplementation in the Treatment of Knee Osteoarthritis

NCT01478386
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Orthovisc, DonJoy HA lite knee brace, Orthovisc injections and DonJoy HA lite knee brace
Other · Device
Lead sponsor
OAD Orthopaedics
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Warrenville, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 22, 2013 · Synced Sep 5, 2026, 9:55 PM EDT
Not listed Phase 1Phase 2 Interventional

Safety and Effectiveness of the PXL-Platinum 330 System

NCT04401865
View directory record Official record
Conditions
Corneal Ectasia, Keratoconus, Pellucid Marginal Corneal Degeneration
Interventions
PXL-330 Platinum device for crosslinking with Peschke riboflavin solution
Combination Product
Lead sponsor
Colorado Eye Consultants/Cornea Consultants of Colorado
Industry
Eligibility
8 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Littleton, Colorado • Highland Park, Illinois • Brecksville, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 24, 2022 · Synced Sep 5, 2026, 9:55 PM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19

NCT04435808
View directory record Official record
Conditions
COVID-19
Interventions
Hydroxychloroquine
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Feb 13, 2022 · Synced Sep 5, 2026, 9:55 PM EDT
Completed Phase 2 Interventional Results available

Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer

NCT01307891
View directory record Official record
Conditions
Breast Cancer, Triple Negative Breast Cancer, Stage IV Breast Cancer, Metastatic Breast Cancer
Interventions
Abraxane alone, Abraxane + Tigatuzumab
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
10
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2017 · Synced Sep 5, 2026, 9:55 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy

NCT03334617
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Durvalumab, Danvatirsen, Ceralasertib, Vistusertib, Olaparib, Oleclumab, Trastuzumab deruxtecan, Cediranib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
528 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
17
States / cities
Duarte, California • Fullerton, California • La Jolla, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2025 · Synced Sep 5, 2026, 9:55 PM EDT
Recruiting Phase 2Phase 3 Interventional

Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

NCT03013998
View directory record Official record
Conditions
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Interventions
Samalizumab (BAML-16-001-S1), BI 836858 (BAML-16-001-S2), Laboratory Biomarker Analysis, Daunorubicin (BAML-16-001-S1), Cytarabine (BAML-16-001-S1), Azacitidine (BAML-16-001-S2), AG-221 (BAML-16-001-S3), Azacitidine (BAML-16-001-S3), Entospletinib (BAML-16-001-S4), Azacitidine (BAML-16-001-S4), Entospletinib (BAML-16-001-S5), Decitabine (BAML-16-001-S5), Entospletinib (BAML-16-001-S6), Daunorubicin (BAML-16-001-S6), Cytarabine (BAML-16-001-S6), Pevonedistat (BAML-16-001-S9), Azacitidine (BAML-16-001-S9), AG-120 (BAML-16-001-S16), Azacitidine (BAML-16-001-S16), Gilteritinib (BAML-16-001-S8 Group 1), Decitabine (BAML-16-001-S8 Group 1), AZD5153 (BAML-16-001-S10), Venetoclax (BAML-16-001-S10), TP-0903 (BAML-16-001-S14), Decitabine (BAML-16-001-S14), Decitabine (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S8 Group 2), AZD5991 (BAML-16-001-S18), Azacitidine (BAML-16-001-S18), SNDX-5613 (BAML-16-001-S17), Azacitidine (BAML-16-001-S17), Venetoclax (BAML-16-001-S17), Gilteritinib (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S12 Arm A), Azacitidine (BAML-16-001-S12 Arm A), Venetoclax (BAML-16-001-S12 Arm B), Azacitidine (BAML-16-001-S12 Arm B), ZE46-0134 (BAML-16-001-S21 Group 1), ficlatuzumab (BAML-16-001-S24), Azacitidine (BAML-16-001-S24), Venetoclax (BAML-16-001-S24), ZE46-0134 (BAML-16-001-S21 Group 2), Bleximenib (BAML-16-001-S25/HO181), Cytarabine (BAML-16-001-S25/HO181), Daunorubicin or Idarubicin (BAML-16-001-S25/HO181), Placebo (BAML-16-001-S25/HO181), Revumenib (BAML-16-001-S26/HO177), Placebo (BAML-16-001-S26/HO177)
Biological · Other · Drug
Lead sponsor
Beat AML, LLC
Other
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2032
U.S. locations
31
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 5, 2026, 9:55 PM EDT
Completed Phase 2 Interventional Results available

Palbociclib and Cetuximab in Metastatic Colorectal Cancer

NCT03446157
View directory record Official record
Conditions
Cancer of the Colon, Colon Cancer, Colon Neoplasms, Colonic Cancer, Neoplasms, Colonic
Interventions
Cetuximab, Palbociclib
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 99 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Sep 5, 2026, 9:55 PM EDT
Not listed Not applicable Interventional

The Effect of Exercise on Wound Healing While Off-loading

NCT04280016
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
Exercise
Behavioral
Lead sponsor
Mercer University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 24, 2021 · Synced Sep 5, 2026, 9:55 PM EDT
Not listed Not applicable Interventional

A Multicentre Prospective Study Evaluating an Off-loading Mattress Overlay System in Healing of Stage 3 Pressure Ulcers

NCT05033470
View directory record Official record
Conditions
Pressure Ulcer
Interventions
Dabir Mattress Overlay System
Device
Lead sponsor
SerenaGroup, Inc.
Network
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Butler, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 3, 2022 · Synced Sep 5, 2026, 9:55 PM EDT
Completed Phase 2 Interventional Results available

Cetuximab Plus Conformal Thoracic Radiotherapy in Patients (Pts) With Inoperable or Unresectable Locally Advanced Non-Small Cell Lung Cancer (LA - NSCLC)

NCT00673738
View directory record Official record
Conditions
Lung Cancer
Interventions
Cetuximab, Conformal Thoracic Radiotherapy (CTRT)
Drug · Radiation
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Oct 7, 2015 · Synced Sep 5, 2026, 9:55 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Pilot Trial of Subjects With Complex Non-healing Diabetic Foot Ulcers Treated With Standard Care Plus Cryopreserved Umbilical Cord Allograft (TTAX01)

NCT03230175
View directory record Official record
Conditions
Non-healing Wound, Non-healing Diabetic Foot Ulcer, Diabetic Foot Infection
Interventions
TTAX01, Surgical resection and debridement, Systemic antibiotics, Off-loading
Biological · Procedure · Drug + 1 more
Lead sponsor
BioTissue Holdings, Inc
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
11
States / cities
Phoenix, Arizona • Sylmar, California • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Sep 5, 2026, 9:55 PM EDT
Recruiting Not applicable Interventional

Spinal Cord Stimulation for Respiratory Rehabilitation in Patients With Chronic Spinal Cord Injury

NCT06019949
View directory record Official record
Conditions
Spinal Cord Injuries, Respiration Disorders
Interventions
Transcutaneous spinal cord stimulator, Respiratory Training
Device
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Sep 5, 2026, 9:55 PM EDT
Completed Not applicable Interventional Results available

Powered Orthotic Exoskeleton Training in Stroke

NCT04241848
View directory record Official record
Conditions
Stroke
Interventions
Keeogo, Ambulation training
Device · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 89 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 9, 2025 · Synced Sep 5, 2026, 9:55 PM EDT
Active, not recruiting Not applicable Interventional

Clinical Utility of an Amniotic Membrane Allograft for Diabetic Foot Ulcer Wound Management

NCT06420245
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
Orion TM Amniotic Membrane Allograft, Standard of Care (SOC)
Device · Procedure
Lead sponsor
Legacy Medical Consultants
Industry
Eligibility
50 Years to 85 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
8
States / cities
Palm Springs, California • San Francisco, California • Vista, California + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 5, 2026, 9:55 PM EDT
Recruiting Phase 4 Interventional

Effect of Amnio-Maxx on the Healing Rate of Chronic Diabetic Foot Ulcers.

NCT07209475
View directory record Official record
Conditions
Diabetic Foot Ulcer (DFU), Amnio-Maxx
Interventions
Amnio-Maxx® Dual Layer Amnion Patch, Standard of Care (Investigator Choice)
Biological · Other
Lead sponsor
Royal Biologics
Industry
Eligibility
18 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
8
States / cities
Burbank, California • Miami, Florida • Stone Mountain, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Sep 5, 2026, 9:55 PM EDT
Terminated Phase 4 Interventional

RESPOND Restoring Equilibrium and Wound Stimulation to Promote Healing Of Non-healing DFUs

NCT01608776
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
MIST Therapy, SOC - Standard of Care
Device · Other
Lead sponsor
Celleration, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 7, 2014 · Synced Sep 5, 2026, 9:55 PM EDT
Active, not recruiting Phase 2 Interventional

PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer

NCT06172127
View directory record Official record
Conditions
HER2-positive Breast Cancer
Interventions
Trastuzumab deruxtecan, Phesgo 1,200 MG / 600 MG / 30,000 UNT Per 15 ML Injection, Phesgo 600 MG / 600 MG / 20,000 UNT in 10 mL Injection
Drug
Lead sponsor
MedSIR
Other
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 5, 2026, 9:55 PM EDT
Suspended Not applicable Interventional Accepts healthy volunteers

Muscle Function After Childbirth

NCT05073224
View directory record Official record
Conditions
Postpartum, Muscle Fatigue, Force Steadiness, Nulligravid, Muscle Weakness
Interventions
Active Straight Leg Raise Test, Active Straight Leg Raise Fatigue Task, Lower Extremity Strength Testing, Ultrasound imaging of abdominal wall
Diagnostic Test · Other
Lead sponsor
Carroll University
Other
Eligibility
20 Years to 35 Years · Female only
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Waukesha, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Sep 5, 2026, 9:55 PM EDT
Completed Not applicable Interventional Results available

PriMatrix for the Management of Diabetic Foot Ulcers

NCT03010319
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
PriMatrix Dermal Repair Scaffold, Secondary Dressings, Offloading device
Device
Lead sponsor
Integra LifeSciences Corporation
Industry
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
17
States / cities
Carlsbad, California • Los Angeles, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Sep 5, 2026, 9:55 PM EDT
Recruiting Phase 1Phase 2 Interventional

Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML

NCT06158828
View directory record Official record
Conditions
AML, Childhood, Aml, Acute Myeloid Leukemia, Pediatric, Acute Myeloid Leukemia
Interventions
Rabbit Anti thymocyte globulin, Busulfan, Fludarabine, Thiotepa, Melphalan, TCR alpha beta / CD19+ depleted haploidentical hematopoietic progenitor cell graft, memory-like natural killer cells, IL-2, Plerixafor, Granulocyte Colony-Stimulating Factor, CliniMACS
Drug · Biological · Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 5, 2026, 9:55 PM EDT
Not yet recruiting Phase 2 Interventional

Using TropoCells(R) Autologous Platelet-Rich Fibrin (PRF) to Treat Chronic Non-Healing Wounds

NCT07318792
View directory record Official record
Conditions
Wound Chronic Draining, Wound Closure
Interventions
Platelet-rich fibrin (PRF)
Device
Lead sponsor
Estar Medical dba Medical Technologies, LTD
Industry
Eligibility
18 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
3
States / cities
Bradenton, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced Sep 5, 2026, 9:55 PM EDT
Completed Phase 1 Interventional

Bevacizumab in Multiple Phase I Combinations

NCT00543504
View directory record Official record
Conditions
Advanced Cancer
Interventions
Bevacizumab, Sorafenib, Erlotinib, Trastuzumab, Lapatinib, Sunitinib, Cetuximab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 29, 2020 · Synced Sep 5, 2026, 9:55 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of Two Heel Protection Devices to Assess Off-loading Via Pressure Mapping.

NCT07734220
View directory record Official record
Conditions
Pressure Injuries
Interventions
HeelMedix Basic & EHOB Waffle
Device
Lead sponsor
Medline Industries
Industry
Eligibility
22 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Northfield, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 5, 2026, 9:55 PM EDT
Recruiting Not applicable Interventional

Clinical Trial Assessing Human Placental Membrane Products and Standard of Care Versus Standard of Care in Nonhealing DFUs and VLUs

NCT06674980
View directory record Official record
Conditions
Pathologic Processes, Diabetes Mellitus, Glucose Metabolism Disorders, Metabolic Diseases, Endocrine System Disease, Diabetic Angiopathies, Vascular Diseases, Cardiovascular Diseases, Leg Ulcer, Skin Ulcer, Skin Diseases, Diabetes Complications, Diabetic Neuropathies, Foot Diseases, Diabetic Foot, Foot Ulcer, Diabetes Mellitus, Type 2, Ulcer, Foot Ulcer Unhealed
Interventions
Standard of Care - DFU, AM/Single - DFU, AM/Double - DFU, Standard of Care - VLU, AM/Single - VLU, AM/Double - VLU
Other
Lead sponsor
C5 Biomedical
Industry
Eligibility
18 Years and older
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Metairie, Louisiana
Source: ClinicalTrials.gov public record
Updated Dec 26, 2024 · Synced Sep 5, 2026, 9:55 PM EDT